Atrial fibrillation: Controversial issues of modern classification, new possibilities of diagnostics and treatment


DOI: https://dx.doi.org/10.18565/therapy.2024.6.156-161

Tarzimanova A.I.

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Abstract. Atrial fibrillation (AF) is one of the most common arrhythmias in the clinic of internal medicine. Structural remodeling of atria with development of their significant dilation and fibrosis indicates a severe course of AF and allows predicting the progression of arrhythmia to its more stable forms. Current review discusses a new classification of AF suggested in recommendations of American College of Cardiology and American Heart Association in 2023, which extends the possibilities of prevention and early detection of the disease. New portable devices play a major role in the diagnosis of such kind of arrhythmia. Modern clinical studies have proven the advantage of early rhythm control strategy comparatively to ventricular rate control. That results in a significant reduction in all-cause mortality, stroke, and major adverse cardiovascular events. These promising results are prognosticating a fundamental change in the approach of cardiologists to the management of patients with AF.
Keywords: methods of atrial fibrillation diagnostics, modern classification of atrial fibrillation, antiarrhythmic therapy, atrial fibrillation
Read entire article

Literature

1. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. с соавт. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(7): 190–260. (Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu. et al. 2020 clinical guidelines for atrial fibrillation and atrial flutter. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(7): 190–260 (In Russ.)).


https://doi.org/10.15829/1560-4071-2021-4594. EDN: FUZAAD.


2. Im S.I., Chun K.J., Park S.-J. et al. Long-term prognosis of paroxysmal atrial fibrillation and predictors for progression to persistent or chronic atrial fibrillation in the Korean population. J Korean Med Sci. 2015; 30(7): 895–902.


https://doi.org/10.3346/jkms.2015.30.7.895. PMID: 26130952. PMCID: PMC4479943.


3. De Vos C.B., Breithardt G., Camm A.J. et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012; 163(5): 887–93.


https://doi.org/10.1016/j.ahj.2012.02.015. PMID: 22607868.


4. Подзолков В.И., Тарзиманова А.И. Современные предикторы прогрессирования фибрилляции предсердий. Рациональная фармакотерапия в кардиологии. 2019; 15(2): 149–158. (Podzolkov V.I., Tarzimanova A.I. Current predictors of atrial fibrillation progression. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2019; 15(2): 149–158 (In Russ.)).


https://doi.org/10.20996/1819-6446-2019-15-2-149-158. EDN: CQFXIK.


5. Saleh K., Haldar S. Atrial fibrillation: A contemporary update. Clin Med (Lond). 2023; 23(5): 437–41.


https://doi.org/10.7861/clinmed.2023-23.5.Cardio2. PMID: 37775166. PMCID: PMC10541273.


6. Joglar J.A., Chung M.K., Armbruster A.L. et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024; 149(1): e1–e156.


https://doi.org/10.1161/CIR.0000000000001193. PMID: 38033089. PMCID: PMC11095842.


7. Халикова М.А., Царегородцев Д.А., Берая М.М. с соавт. Преимущества применения портативного кардиомонитора в амбулаторном наблюдении за пациентами с пароксизмальной формой фибрилляции предсердий. Кардиоваскулярная терапия и профилактика. 2022; 21(6): 32–41. (Khalikova M.A., Tsaregorodtsev D.A., Beraya M.M. et al. Advantages of using a portable cardiac monitor in outpatients with paroxysmal atrial fibrillation. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(6): 32–41 (In Russ.)).


https://doi.org/10.15829/1728-8800-2022-3225. EDN: OCUZAP.


8. Tarakji K.G., Wazni O.M., Callahan T. et al. Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: The iTransmit study. Heart Rhythm. 2015; 12(3): 554–59.


https://doi.org/10.1016/j.hrthm.2014.11.015. PMID: 25460854.


9. Gupta D., Vijgen J., Potter T. et al. Quality of life and healthcare utilisation improvements after atrial fibrillation ablation. Heart. 2021; 107(16): 1296–1302.


https://doi.org/10.1136/heartjnl-2020-318676. PMID: 33952593. PMCID: PMC8327410.


10. Packer D.L., Mark D.B., Robb R.A. et al.; CABANA Investigators. Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: Study rationale and design. Am Heart J. 2018; 199: 192–99.


https://doi.org/10.1016/j.ahj.2018.02.015. PMID: 29754661. PMCID: PMC6517320.


11. Camm A.J., Naccarelli G.V., Mittal S. et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 79(19): 1932–48.


https://doi.org/10.1016/j.jacc.2022.03.337. PMID: 35550691.


12. Han S., Jia R., Cen Z. et al. Early rhythm control vs. rate control in atrial fibrillation: A systematic review and meta-analysis. Front Cardiovasc Med. 2023; 10: 978637.


https://doi.org/10.3389/fcvm.2023.978637. PMID: 36815025. PMCID: PMC9939510.


13. Kirchhof P., Camm A.J., Goette A. et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383(14): 1305–16.


https://doi.org/10.1056/nejmoa2019422. PMID: 32865375.


14. Тарасов А.В., Косых С.А., Бушуева Е.В. с соавт. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019; 21(1): 81–86. (Tarasov A.V., Kosykh S.A., Bushueva E.V. et al. Comparison of antiarrhythmic medications propafenone and amiodarone injection forms effectiveness in medicamentous cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019; 21(1): 81–86 (In Russ.)).


https://doi.org/10.26442/20751753.2019.1.190286. EDN: ZFHBML.


15. Фомина И.Г., Тарзиманова А.И., Ветлужский А.В. с соавт. Пропафенон при восстановлении и сохранении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое мультицентровое исследование в РФ. Рациональная фармакотерапия в кардиологии. 2006; 2(1): 37–40. (Fomina I.G., Tarzimanova A.I., Vetluzsky A.V. et al. Propafenone for sinus rhythm recovery and support in patients with persistent form of auricular fiblillation. PROMETHEUS – opened multicenter study in Russian Federation. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2006; 2(1): 37–40 (In Russ.)). EDN: JTLVEP.


16. Khan I.A., Mehta N.J., Gowda R.M. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 89(2–3): 239–48.


https://doi.org/10.1016/s0167-5273(02)00477-1. PMID: 12767548.


17. Kirchhof P., Andresen D., Bosch R. et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380(9838): 238–46.


https://doi.org/10.1016/s0140-6736(12)60570-4. PMID: 22713626.


18. Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопасность применения пропафенона (Пропанорма©) и амиодарона (Кордарона©) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010; 15(4): 55–71. (Miller O.N., Starichkov S.A., Pozdnyakov Yu.M. et al. Effectiveness and safety of propafenone (Propanorm©) and amiodarone (Cordarone©) in patients with atrial fibrillation, arterial hypertension, coronary heart disease, and chronic heart failure with intact left ventricular systolic function. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2010; 15(4): 55–71 (In Russ.)). EDN: MUENJV.


About the Autors

Aida I. Tarzimanova, MD, Dr. Sci. (Medicine), professor of the Department of faculty therapy No. 2 of N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Address: 119048, Moscow, 24 Efremova St.
E-mail: tarzimanova@mail.ru
ORCID: https://orcid.org/0000-0001-9536-8307


Similar Articles

Back to Content

Бионика Медиа